Pfizer Launches Web Site Showing Drug Risks

The big drugmaker plans to promote the site by working with medical and patient advocacy groups, as well as with online advertising on other web sites targeting medical professionals and patients, according to theAssociated Press.

The detailed site includes sections written for patients and for health professionals, with explanations in simple English, engaging graphics and clips of video hosts discussing important points. There is also info on reporting side effects to the FDA's Medwatch program, the AP adds. Here is the new site, take a look and tell us what you think).

There are also sections that include a timeline covering steps taken to monitor safety from initial testing until after marketing and how the pharmaceutical industry, regulatory agencies and health professionals work together and with patients to try to ensure safety. Another section gives some insight on weighing risks, showing how people tend to fear unlikely things, like being in an airplane crash, more than common risks such as heart disease, the AP reports.

A fourth section details what patients should know, tell their doctor and ask about every time they are prescribed a medicine; how to decide whether its risks are acceptable, and how to interpret what's on a prescription bottle.

One doctor who is a frequent industry critic calls the site a good first step in communicating to the public the need to balance the risks and benefits of medicines. Harlan Krumholz, director of the Yale-New Haven Hospital Center for Outcomes Research and Evaluation, tells the AP that Pfizer is "trying to do the right thing" to help people put drug safety in perspective.

"The spirit of what they're doing is great," he says. "Whether this is the most effective way to assist patients to make the best decisions for themselves, time will tell."

Mike Zarski, chief information officer of the American Osteopathic Association, evaluated the site as a potential resource its member physicians could show patients. He concluded it would be good. "It's the kind of information I would want to provide my family," Zarski said, tells the AP, but noted Pfizer did not follow his suggestion of keeping the site totally separate from the corporate Web site.

Gretchen Dieck, Pfizer's head of safety and risk management, tells the AP the drugmaker decided to create the site after focus groups of doctors, patients, regulators and others showed an interest in having such information.

The effort follows recent steps by Pfizer to address concerns about industry behavior, including changing its funding for continuing medical education programs to eliminate commercial aspects and supporting PhRMA's updated policy limiting gifts from sales representatives to doctors.

Source: Associated Press

3 Comments

Sep 16, 2008 - 12:50am

I cannot claim to have done a thorough review of the site - just a skimming of some of its parts.

In the "safety timeline" section, the smiley cybot tells us, "Rare side effects can sometimes only be identified after thousands of patients have taken the medication." All this is in the context of post-approval info.

The statement is, of course, true. But what is not said is that, in 51% of new drugs, serious AEs appear post-approval. So the "rare" and "sometimes" language, while not false, is certainly misleading.

It is interesting that this story appears at the same time as the FDA "guide to ads" does. Is this the sort of "help" we will be left with when preemption takes away the possibility of discovery and genuine accountability?

It is a brave new world, indeed. God help us.

Sep 16, 2008 - 5:56am

The new site sickens me.

I do not need a tutorial on perceiving the dangers of swallowing their products- they gave me a crash course. Not all dangers are quite so coincidental as they would have you believe.

As for responsibility- they have taken none.

http://www.efnj.com/media/pdf/ezine/Epilepsy%20News%20Issue%205.pdf

Where is the information for professionals? I, too, did only a brief skimming of the site, but it appears to be rather juvenile. It reminds me of the state mandated communications to TennCare members to be on the 6th grade reading level. A waste of time for most adults I imagine who would be browsing a drugmaker's website.